NCT04115956View on ClinicalTrials.gov

A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 6, 2020

Primary Completion Date

January 5, 2022

Study Completion Date

January 5, 2022

Conditions
AL Amyloidosis
Interventions
DRUG

Melphalan-Flufenamide (Melflufen)

Treatment consist of i.v. melflufen on Day 1 of each 28-day cycle.

DRUG

Dexamethasone

Dexamethasone 40 mg (20 mg at investigator's discretion) administered on Days 1 and 2 of each 28-day cycle.

Trial Locations (9)

11528

Alexandra General Hospital of Athens, Athens

69120

Universitätsklinikum Heidelberg, Heidelberg

70852

Fakultní Nemocnice Ostrava, Ostrava - Poruba

87000

Centre Hospitalier Universitaire de Limoges, Limoges

9112001

Hadassah University Hospital Ein Kerem, Jerusalem

02111

Boston University Medical Center, Boston

0372

Oslo University Hospital - Rikshospitalet, Oslo

08036

Hospital Clinic de Barcelona, Barcelona

NW1 2BU

University College London Hospitals NHS Foundation Trust, London

Sponsors

Lead Sponsor

Oncopeptides AB

Collaborators (1)

PRA Health Sciences
All Listed Sponsors
collaborator

PRA Health Sciences

INDUSTRY

lead

Oncopeptides AB

INDUSTRY

NCT04115956 - A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis | Biotech Hunter | Biotech Hunter